tafluprost

(redirected from Zioptan)

tafluprost

(ta-floo-prost) ,

Zioptan

(trade name)

Classification

Therapeutic: ocular hypotensive agent
Pharmacologic: prostaglandins
Pregnancy Category: C

Indications

Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Action

Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects

↓ intraocular pressure.

Pharmacokinetics

Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.

Time/action profile (↓ in intraocular pressure)

ROUTEONSETPEAKDURATION
Ophthwithin 2–4 hr12 hr24 hr

Contraindications/Precautions

Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hyperemia (most frequent)
  • blurred vision
  • cataract
  • permanent iris pigmentation
  • eyelid pigmentation
  • lash pigmentation/increased thickness/↑ number
  • macular edema
  • ocular stinging/irritation

Interactions

Drug-Drug interaction

Note noted.

Route/Dosage

Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).

Availability

Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Nursing implications

Nursing assessment

  • Measure intraocular pressure periodically during therapy.

Potential Nursing Diagnoses

Readiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Reduction of intraocular pressure.
References in periodicals archive ?
at Request Letter 2013-5788; see also MERCK, PATIENT INFORMATION: ZIOPTAN 5, https://www.merck.com/ product/usa/pi_circulars/z/zioptan/zioptan_ppi.pdf [http://perma.cc/7RC6-N85R] (last updated Aug.
Of the four prostaglandin analogs, three have no human eye data, bimatoprost (Lumigan), tafluprost (Zioptan), and travoprost (Travatan Z).
These include glaucoma treatment pill Zioptan, hepatitis C drug Victrelis, and an extended version of its combination type-2 diabetes pill, Janumet XR.
Merck on Tuesday announced that the FDA has approved it's eye solution Zioptan for the treatment of a common eye condition.
Zioptan (tafluprost ophthalmic solution) is now able to be used in the US for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Approval of this drug was based on two Phase III clinical trials which showed that Zioptan once-daily lowered intraocular pressure at three and six months.
The two ophthalmic preparations are ocriplasmin (jetrea; symptomatic vitreomacular adhesions) and tafluprost (Zioptan; glaucoma).